Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4622932 | 0.99 | BACE1 (0.59) | BACE1MCHR1ITGB3ITGA2BFFAR1 | |
| SCHEMBL1268345 | 0.87 | MCHR1 (0.66) | BACE1MCHR1ITGB3ITGA2BFFAR1 | |
| Hydrochloric Acid SCHEMBL4622184 | 0.86 | MCHR1 (0.65) | BACE1MCHR1ITGB3ITGA2BFFAR1 | |
| SCHEMBL361026 | 0.86 | BACE1 (0.65) | BACE1MCHR1ITGB3ITGA2BFFAR1 | |
| Hydrochloric Acid SCHEMBL4621262 | 0.85 | BACE1 (0.64) | BACE1MCHR1ITGB3ITGA2BFFAR1 | |
| SCHEMBL1269557 | 0.83 | BACE1 (0.67) | BACE1MCHR1ITGB3ITGA2BFFAR1 | |
| SCHEMBL361018 | 0.83 | BACE1 (0.67) | BACE1MCHR1ITGB3ITGA2BFFAR1 | |
| SCHEMBL14440082 | 0.83 | MCHR1 (0.60) | BACE1MCHR1ITGB3ITGA2BHRH3 | |
| Hydrochloric Acid SCHEMBL4622556 | 0.82 | BACE1 (0.66) | BACE1MCHR1ITGB3ITGA2BFFAR1 | |
| Water SCHEMBL4978875 | 0.82 | BACE1 (0.66) | BACE1MCHR1ITGB3ITGA2BFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305219-A1 | Pharmaceutical preparations coated with a copolyvidone-containing coating | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | claimed |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2009-11-05 | — | — | US | claimed |
| US-20050085553-A1 | Remedies for mild recognition deflict | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-21 | — | — | US | claimed |
| EP-1459764-A1 | REMEDIES FOR MILD RECOGNITION DEFLICT | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | claimed |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-01-29 | — | — | US | claimed |
| EP-1334732-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | claimed |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-26 | — | — | US | disclosed |
| CN-122071471-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-22 | — | — | CN | disclosed |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| CN-122010945-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010946-A | Heterocyclic compounds | 武田药品工业株式会社 | 2026-05-12 | — | — | CN | disclosed |
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20050148650-A1 | Antidepressant | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-07 | — | — | US | disclosed |
| US-20050085553-A1 | Remedies for mild recognition deflict | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-21 | — | — | US | disclosed |
| WO-2005032537-A1 | METHOD FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-14 | — | — | WO | disclosed |
| EP-1481679-A1 | ANTIDEPRESSANT | Takeda Chemical Industries, Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-1459764-A1 | REMEDIES FOR MILD RECOGNITION DEFLICT | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1334732-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | BACE1 4855/4885MCHR1 1553/4885ITGB3 3211/4885 |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | BACE1 4855/4885MCHR1 1553/4885ITGB3 3211/4885 |
| US-20050085553-A1 | Remedies for mild recognition deflict | ACHE, CHAT, PSEN1 | BACE1 6/4885MCHR1 1973/4885ITGB3 4360/4885 |
| US-20050148650-A1 | Antidepressant | AKT1S1, AKT1, AKT2 | BACE1 327/4885MCHR1 659/4885ITGB3 3978/4885 |
| US-20260092033-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, MTNR1B | BACE1 350/4885MCHR1 22/4885ITGB3 4668/4885 |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | GRIN1, GRIN3A, GRIN2A | BACE1 417/4885MCHR1 336/4885ITGB3 1602/4885 |
| US-20260146047-A1 | MACROCYCLIC HETEROCYCLE COMPOUNDS AND USE THEREOF | HCRTR2, HCRTR1, NPY1R | BACE1 1249/4885MCHR1 28/4885ITGB3 3466/4885 |
| US-12630534-B2 | 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds as GPR139 antagonists for the treatment of e.g. depression | GPR139, OPRL1, GRIN2C | BACE1 140/4885MCHR1 464/4885ITGB3 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.